Date: Sunday, October 21, 2018
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Figure 1: DNA damage levels: Healthy individuals (n=9), HCV-CV patients (n=13), HCV+CV at pretreatment (n=32), EOT (end of treatment) (n=32), 6 months (n=19) and 12 months (n=23).
Figure 2: Repair genes expression levels: HCV-CV patients (n=13), HCV+CV at pretreatment (n=32), EOT (end of treatment) (n=32), 6 months (n=19) and 12 months (n=23).
The reported elevated levels of chromosomal breaks and the reduced expression of all tested DNA repair genes with DAAs in treating HCV/CV+ instigate deeper and more extended studies to understand the nature of our findings and evaluate the safety of these drugs.
To cite this abstract in AMA style:Hegazy MT, Allam W, Hussein MA, Zoheir N, Quartuccio L, Cacoub P, Doss W, Ellawindi MI, Fawzy M, Guillevin L, El Ray A, El Raziky MES, El Serafy M, El Khamisy S, Ragab G. DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/dna-damage-and-repair-in-patients-with-cryoglobulinemic-vasculitis-treated-with-direct-anti-hcv-drugs/. Accessed June 17, 2021.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/dna-damage-and-repair-in-patients-with-cryoglobulinemic-vasculitis-treated-with-direct-anti-hcv-drugs/